The Vaccine Group, a University of Plymouth spinout company, has successfully completed a project to develop a transmissible vaccine for use in the rats that spread Lassa fever and to reduce its threat to humans.
A small-scale trial of a candidate vaccine in controlled conditions has shown it could be transmitted between rats and significantly improve their immunity to the disease. Technology has also been developed that has the potential to scale up the vaccine for commercial production.
The work, led by University of California, Davis, was funded by the US Defense Advanced Project Research Agency (DARPA) and saw scientists at The Vaccine Group collaborating with academic partners from around the world.
Their work confirmed Lassa fever virus to be circulating in mastomys rat populations in West Africa, and isolated a species-specific cytomegalovirus (CMV) found to be widespread in these populations.
The isolated CMV strains were down-selected based upon growth parameters in vitro, and a candidate vector strain was selected for use as a viral vector for the vaccine candidate.
Two potentially protective antigens were identified from Lassa fever virus, and a lead candidate was selected with a transgene inserted into a single site in the CMV vaccine vector. In addition, a continuous cell line with the potential for commercial scale production of the vaccine was developed from mastomys rat tissues.
A small-scale trial batch of the candidate vaccine was used in controlled studies under biosecurity containment and shown to be immunogenic in inoculated animals and transmissible to naïve co-housed cagemates.
The vaccine was also shown to reduce Lassa fever virus infection and excretion after challenge at highly significant levels. In addition, the vaccine is constructed to achieve the necessary level of Lassa virus immunity before gradually losing the Lassa virus gene, which restores the vaccine to naturally occurring wild type CMV already present in animals.
The Vaccine Group was launched to commercialise the research of Dr Michael Jarvis, Associate Professor (Reader) in Virology and Immunology at the University of Plymouth, and is developing vaccines based on the CMV virus.
Other herpesvirus-based vaccines the group is developing include those to combat COVID-19, African swine fever, Streptococcus suis (a disease in pigs that can cause meningitis in humans), and porcine reproductive and respiratory syndrome virus.
Its future work linked to Lassa fever will use the vaccine challenge study data to refine the computer model developed to predict the outcomes of Lassa fever control interventions.
Next steps will include further controlled vaccine transmission and efficacy studies, technical transfer of the vaccine production system to a manufacturing partner for scale-up and pilot field studies in Lassa fever virus-endemic regions.
Continued engagement with stakeholders with an interest in the control of Lassa fever in West Africa will be important to identify the environment in which the tools developed by this project can be deployed.
The Vaccine Group (TVG) Ltd: Vaccine Solutions for the 21st Century
Commercialisation of patented platform technology for the development of vaccines for use in infection control and for a rapid response to pathogens affecting human and animal health. Target pathogens include COVID-19, avian influenza A, Ebola and Marburg viruses, MERS and SARS coronaviruses and Rift Valley fever virus
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
